290 related articles for article (PubMed ID: 12494472)
1. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer.
Salgado R; Junius S; Benoy I; Van Dam P; Vermeulen P; Van Marck E; Huget P; Dirix LY
Int J Cancer; 2003 Feb; 103(5):642-6. PubMed ID: 12494472
[TBL] [Abstract][Full Text] [Related]
2. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.
Zhang GJ; Adachi I
Anticancer Res; 1999; 19(2B):1427-32. PubMed ID: 10365118
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.
Bachelot T; Ray-Coquard I; Menetrier-Caux C; Rastkha M; Duc A; Blay JY
Br J Cancer; 2003 Jun; 88(11):1721-6. PubMed ID: 12771987
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients.
Ahmed OI; Adel AM; Diab DR; Gobran NS
Egypt J Immunol; 2006; 13(2):61-8. PubMed ID: 18689272
[TBL] [Abstract][Full Text] [Related]
5. Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions.
Coskun U; Bukan N; Sancak B; Günel N; Ozenirler S; Unal A; Yucel A
Neoplasma; 2004; 51(3):209-13. PubMed ID: 15254675
[TBL] [Abstract][Full Text] [Related]
6. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.
Humphrey PA; Halabi S; Picus J; Sanford B; Vogelzang NJ; Small EJ; Kantoff PW
Clin Genitourin Cancer; 2006 Mar; 4(4):269-74. PubMed ID: 16729910
[TBL] [Abstract][Full Text] [Related]
8. Tumor marker CA 15-3 in breast cancer patients.
Fejzić H; Mujagić S; Azabagić S; Burina M
Acta Med Acad; 2015; 44(1):39-46. PubMed ID: 26062696
[TBL] [Abstract][Full Text] [Related]
9. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
10. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
[TBL] [Abstract][Full Text] [Related]
11. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G
Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
[TBL] [Abstract][Full Text] [Related]
12. Circulating soluble Fas concentration in breast cancer patients.
Ueno T; Toi M; Tominaga T
Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
[TBL] [Abstract][Full Text] [Related]
13. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
14. Soluble immunological parameters and early prognosis of renal cell cancer patients.
Kallio JP; Tammela TL; Marttinen AT; Kellokumpu-Lehtinen PL
J Exp Clin Cancer Res; 2001 Dec; 20(4):523-8. PubMed ID: 11876546
[TBL] [Abstract][Full Text] [Related]
15. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival.
Benoy IH; Salgado R; Van Dam P; Geboers K; Van Marck E; Scharpé S; Vermeulen PB; Dirix LY
Clin Cancer Res; 2004 Nov; 10(21):7157-62. PubMed ID: 15534087
[TBL] [Abstract][Full Text] [Related]
16. Circulating levels of transforming growth factor-βeta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer.
Divella R; Daniele A; Savino E; Palma F; Bellizzi A; Giotta F; Simone G; Lioce M; Quaranta M; Paradiso A; Mazzocca A
Anticancer Res; 2013 Apr; 33(4):1491-7. PubMed ID: 23564790
[TBL] [Abstract][Full Text] [Related]
17. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
[TBL] [Abstract][Full Text] [Related]
18. Receptor activator for nuclear factor κ B expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis.
Zhang L; Teng Y; Zhang Y; Liu J; Xu L; Qu J; Hou K; Yang X; Liu Y; Qu X
J Clin Pathol; 2012 Jan; 65(1):36-40. PubMed ID: 22049226
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma.
Egler RA; Burlingame SM; Nuchtern JG; Russell HV
Clin Cancer Res; 2008 Nov; 14(21):7028-34. PubMed ID: 18980999
[TBL] [Abstract][Full Text] [Related]
20. Patterns of metastatic breast carcinoma: influence of tumour histological grade.
Porter GJ; Evans AJ; Pinder SE; James JJ; Cornford EC; Burrell HC; Chan SY; Cheung KL; Robertson JF
Clin Radiol; 2004 Dec; 59(12):1094-8. PubMed ID: 15556591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
